Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.

Abstract: The invention described herein relates to certain 4-oxo-2-thioxo-1,2,3,4-tetrahydro-7-quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

Abstract: There is provided a medicament dispenser comprising a body, a medicament container and reset means for resetting a mechanical mechanism after actuation thereof, wherein the reset means comprises a reset coupling. The coupling is reversibly deformable in response to the application of non-mechanical energy thereto. The non-mechanical energy may comprise heat energy, electrical current energy, electrical field energy or magnetic field energy.

Abstract: The invention relates to a compound of formula (I): wherein all variables are as defined herein and to pharmaceutical compositions, methods of using, and processes for preparing the same.

Abstract: Disclosed is a method for preparing (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates thereof, such as the (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride salt via dynamic kinetic resolutions.

Abstract: Novel calcilytic compounds and methods of using them are provided.

Abstract: A valve for use with an aerosol container including a valve body, a valve stem having a dispensing passage, and a sealing ring contacting the valve stem. The sealing ring includes a sealing portion. The valve stem is slidably moveable relative to the sealing ring from a valve-closed position to a valve-open position. The interior of the valve body is in communication with the dispensing passage when the valve stem is in the valve-open position. The sealing ring also includes a wiper component to wipe the valve stem. The valve is preferably a metering valve.

Abstract: A nozzle for dispensing a viscous material from a source of the viscous material. The nozzle includes a dispensing orifice, a nozzle throat in flow communication with that orifice; and a transition in flow communication with the nozzle throat and the source of viscous material. These portions of the nozzle have a specific size relationship.

Abstract: A method and package for storing a pressurized container which is filled with a drug formulation at a predetermined pressure. The drug formulation includes a mixture of a drug and a propellant. The package which encloses the pressurized container substantially prevents ingression of water vapor and particulate matter into the package while permitting egression of the propellant which may leak from the pressurized container.

Abstract: A pharmaceutical composition comprising Compound (I), characterised in that the composition comprises 2 to 12 mg of Compound (I) in a pharmaceutically acceptable form and optionally a pharmaceutically acceptable carrier therefor, the use of such a composition in medicine, processes for the preparation of such a composition and intermediate composition useful in such a process.

Abstract: A compound of formula (I): 1

Abstract: A combination of 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7,-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridinecarboxamide or a salt thereof and paclitaxel and its analogs or derivatives.

Abstract: 1

Abstract: A method for the treatment and/or prophylaxis of Type II diabetes, which method comprises the administration, to a human or non-human mammal, of an effective non-toxic pharmaceutically acceptable amount of an NO synthase inhibitor, such as aminoguanidine, or a pharmaceutically acceptable derivative thereof.

Abstract: A method and apparatus for automatically transferring a predetermined quantity of a sterile liquid to a vial containing a dry medicament for hydrating the medicament and then transferring the hydrated medicament to a container. To hydrate the medicament, a needle is positioned through a vial septum of the vial and an artificial sensor senses when the needle has been positioned through the vial septum and actuates a pump to transfer a predetermined quantity of sterile liquid into the vial. The needle is then removed from the vial septum and the vial is shaken to mix the liquid and medicament. To transfer the hydrated medicament to a container, another needle is positioned through the vial septum. An artificial sensor senses when the needle has been positioned through the vial septum and actuates the pump to transfer the hydrated medicament to the container.

Abstract: This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecule proteins.